A high-level Indian delegation, led by Raja Bhanu of India's Pharmaceuticals Export Promotion Council (Pharmexcil), met on Sunday with key figures in Egypt's fast-growing pharmaceutical sector to boost bilateral cooperation and trade.
The delegation included senior representatives from India's pharmaceutical industry, focusing on opportunities in generics, biosimilars, and vaccines—fields where India holds global leadership. Egypt's pharmaceutical market is projected to expand from $5.1 billion in 2024-25 to $5.7 billion in 2025-26, offering substantial potential for strategic partnerships and investment.
Ambassador Suresh K. Reddy of India to Egypt emphasized the rising momentum in bilateral pharmaceutical relations, stating: “India has long been a trusted partner in the global pharmaceutical industry, and Egypt’s dynamic healthcare sector offers an ideal platform for deeper collaboration. The Embassy remains committed to facilitating partnerships that benefit not only our two countries, but also the wider MENA region.”
Raja Bhanu highlighted India's role in aiding Egypt's healthcare goals, noting: “India’s pharmaceutical industry is known for delivering high-quality, affordable medicines. As Egypt expands healthcare coverage and strengthens local manufacturing capacity, Indian companies are well positioned to collaborate with Egyptian counterparts, helping to improve access to essential medicines for all.”
Cooperation targets priority areas such as generic medicines, clinical research, biotechnology, and vaccine production. The two nations are exploring joint ventures in pharmaceutical manufacturing and research and development to position Egypt as a regional hub for production and trade. The visit also launches new initiatives to spur investment, knowledge exchange, and innovation in healthcare. Pharmexcil and the Indian Embassy will keep supporting India-Egypt partnerships by leveraging shared expertise and opportunities.
